Undisclosed glial cell surface molecule

The "Undisclosed glial cell surface molecule" is a proprietary target for radiopharmaceutical development, specifically identified for its high expression on the surface of glial cells in glioblastoma (GBM) and other glial-derived tumors [1, 2]. It is the primary target for the theranostic pair LNTH-2505 and EVG-311, which were integrated into the Lantheus Holdings pipeline following the acquisition of Evergreen Theragnostics in early 2025 [6, 11]. LNTH-2505 is a 68Ga-labeled radiodiagnostic tracer designed for positron emission tomography (PET) imaging to enable the precise localization and monitoring of glioblastoma [2, 4]. EVG-311 is the corresponding radiotherapeutic candidate, typically utilizing a therapeutic isotope such as 177Lu to deliver targeted radiation directly to tumor cells expressing this molecule [6, 30]. While the specific protein identity remains undisclosed in public corporate disclosures, the target is characterized as a specific marker for malignant glial cells, offering a potential novel avenue for the diagnosis and treatment of aggressive brain cancers with significant unmet medical needs [2, 3].

Other names

Undisc. glial cell surface moleculeGlial cell surface moleculeUndisclosed glioblastoma target

Radiodiagnostic and radiotherapeutic targeting of glial cell surface markers